KYNB
Kyntra Bio, Inc.
Price Chart
Latest Quote
$6.94
+0.00 (+0.00%)
Current Price
| Previous Close | $6.94 |
| Open | $7.00 |
| Day High | $7.49 |
| Day Low | $6.88 |
| Volume | 77,856 |
Stock Information
| Shares Outstanding | 4.05M |
| Total Debt | $19.25M |
| Cash Equivalents | $87.24M |
| Revenue | $7.44M |
| Net Income | $-56.57M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $28.09M |
| EPS (TTM) | $-13.99 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-5.38M |
| Sales | $7.44M |
| Income | $-56.57M |
| Book/sh | $-10.82 |
| Cash/sh | $21.55 |
| Employees | 34 |
Financial Ratios
| Quick Ratio | 3.42 |
| Current Ratio | 3.60 |
Returns & Margins
| ROA | -20.17% |
| Gross Margin | -253.78% |
| Operating Margin | -369.07% |
| Profit Margin | 2199.42% |
Ownership
| Insider Ownership | 2.02% |
| Institutional Ownership | 25.57% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.71 |
| P/S | 3.78 |
| P/B | -0.64 |
Analyst Data
| Recommendation | none |
| Target Price | $43.00 |
Technical Indicators
| SMA20 | $6.85 |
| SMA50 | $6.97 |
| SMA200 | $8.53 |
| RSI | 54.36 |
| ATR | 0.3503 |
| Shares Float | 3.56M |
| Short Float | 2.93% |
| Short Ratio | 14.25 |
| Volatility | 0.99 |
| Rel Volume | 2.22 |
Performance History
| Week | +0.43% |
| Month | +1.31% |
| Quarter | +2.21% |
| 6 Months | -18.93% |
| YTD | -24.24% |
| Year | +27.57% |
| 3 Years | -98.34% |
| 5 Years | -98.94% |
| 10 Years | -98.13% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $6.94 | 77,856 |
| 2026-06-24 | $6.94 | 4,100 |
| 2026-06-23 | $6.97 | 12,100 |
| 2026-06-22 | $6.88 | 4,600 |
| 2026-06-18 | $6.70 | 15,600 |
| 2026-06-17 | $6.91 | 8,400 |
| 2026-06-16 | $6.91 | 6,200 |
| 2026-06-15 | $6.87 | 10,100 |
| 2026-06-12 | $7.13 | 461,300 |
| 2026-06-11 | $6.76 | 6,300 |
| 2026-06-10 | $6.69 | 11,300 |
| 2026-06-09 | $6.69 | 19,400 |
| 2026-06-08 | $6.63 | 12,500 |
| 2026-06-05 | $6.71 | 6,800 |
| 2026-06-04 | $6.81 | 3,800 |
| 2026-06-03 | $6.81 | 5,800 |
| 2026-06-02 | $6.84 | 2,700 |
| 2026-06-01 | $6.90 | 18,700 |
| 2026-05-29 | $6.90 | 6,600 |
| 2026-05-28 | $7.02 | 7,300 |
| 2026-05-27 | $7.01 | 9,300 |
| 2026-05-26 | $6.85 | 6,000 |
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
đ° Latest News
Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ...
GuruFocus.com âĸ 2026-05-12T07:07:50ZKyntra Bio (KYNB) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-11T22:10:32Z
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-11T22:05:06Z
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-07T12:50:11Z
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2026-04-14T16:00:03Z
Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ...
GuruFocus.com âĸ 2026-03-17T03:00:30ZKyntra Bio (KYNB) Q4 2025 Earnings Call Transcript
Motley Fool âĸ 2026-03-16T22:08:29Z
Kyntra Bio: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-16T20:20:35ZMonte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks âĸ 2026-03-12T14:00:03Z
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates
Zacks âĸ 2026-03-09T21:20:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $556,000 | $15,561,000 | $3,962,000 | $20,280,000 |
| Cost Of Revenue | $556,000 | $15,561,000 | $3,962,000 | $20,280,000 |
| Total Revenue | $6,440,000 | $29,621,000 | $46,803,000 | $140,734,000 |
| Operating Revenue | $6,440,000 | $29,504,000 | $46,803,000 | $140,734,000 |
| Expenses | ||||
| Interest Expense | $8,759,000 | $8,247,000 | $8,095,000 | $1,440,000 |
| Total Expenses | $51,782,000 | $160,583,000 | $356,918,000 | $441,759,000 |
| Other Income Expense | $-7,136,000 | $-19,454,000 | $-12,606,000 | - |
| Net Non Operating Interest Income Expense | $-5,816,000 | $-2,951,000 | $-501,000 | $6,156,000 |
| Interest Expense Non Operating | $8,759,000 | $8,247,000 | $8,095,000 | $1,440,000 |
| Operating Expense | $51,226,000 | $145,022,000 | $352,956,000 | $421,479,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-58,204,000 | $-153,098,000 | $-322,970,000 | $-293,654,000 |
| Net Interest Income | $-5,816,000 | $-2,951,000 | $-501,000 | $6,156,000 |
| Interest Income | $2,943,000 | $5,296,000 | $7,594,000 | $7,596,000 |
| Normalized Income | $-51,082,272 | $-133,678,122 | $-310,376,606 | $-293,654,000 |
| Net Income From Continuing And Discontinued Operation | $183,452,000 | $-47,579,000 | $-284,232,000 | $-293,654,000 |
| Total Operating Income As Reported | $-45,895,000 | $-150,416,000 | $-322,721,000 | $-301,025,000 |
| Net Income Common Stockholders | $183,452,000 | $-47,579,000 | $-284,232,000 | $-293,654,000 |
| Net Income | $183,452,000 | $-47,579,000 | $-284,232,000 | $-293,654,000 |
| Net Income Including Noncontrolling Interests | $183,452,000 | $-47,579,000 | $-284,232,000 | $-293,654,000 |
| Net Income Discontinuous Operations | $241,656,000 | $105,519,000 | $38,738,000 | - |
| Net Income Continuous Operations | $-58,204,000 | $-153,098,000 | $-322,970,000 | $-293,654,000 |
| Pretax Income | $-58,294,000 | $-153,367,000 | $-323,222,000 | $-294,869,000 |
| Special Income Charges | $-7,136,000 | $-19,454,000 | $-12,606,000 | $0 |
| Interest Income Non Operating | $2,943,000 | $5,296,000 | $7,594,000 | $7,596,000 |
| Operating Income | $-45,342,000 | $-130,962,000 | $-310,115,000 | $-301,025,000 |
| Gross Profit | $5,884,000 | $14,060,000 | $42,841,000 | $120,454,000 |
| Earnings From Equity Interest Net Of Tax | - | - | $2,638,000 | $1,573,000 |
| Per Share | ||||
| Diluted EPS | $45.37 | $-12.00 | $-73.00 | $-78.50 |
| Basic EPS | $45.37 | $-12.00 | $-73.00 | $-78.50 |
| Other | ||||
| Tax Effect Of Unusual Items | $-14,272 | $-34,122 | $-12,606 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-41,651,000 | $-122,974,000 | $-292,591,000 | $-282,825,000 |
| Total Unusual Items | $-7,136,000 | $-19,454,000 | $-12,606,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-7,136,000 | $-19,454,000 | $-12,606,000 | $0 |
| Reconciled Depreciation | $748,000 | $2,692,000 | $9,930,000 | $10,604,000 |
| EBITDA (Bullshit earnings) | $-48,787,000 | $-142,428,000 | $-305,197,000 | $-282,825,000 |
| EBIT | $-49,535,000 | $-145,120,000 | $-315,127,000 | $-293,429,000 |
| Diluted Average Shares | $4,043,000 | $4,001,760 | $3,892,120 | $3,743,280 |
| Basic Average Shares | $4,043,000 | $4,001,760 | $3,892,120 | $3,743,280 |
| Diluted NI Availto Com Stockholders | $183,452,000 | $-47,579,000 | $-284,232,000 | $-293,654,000 |
| Tax Provision | $-90,000 | $-269,000 | $-252,000 | $358,000 |
| Other Special Charges | $6,583,000 | - | - | - |
| Restructuring And Mergern Acquisition | $553,000 | $19,454,000 | $12,606,000 | $0 |
| Research And Development | $23,517,000 | $95,692,000 | $266,473,000 | $296,791,000 |
| Selling General And Administration | $27,709,000 | $49,330,000 | $86,483,000 | $124,688,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-30,038,000 | $-225,602,000 | $-204,166,000 | $-21,447,000 |
| Total Assets | $119,594,000 | $214,525,000 | $423,529,000 | $610,087,000 |
| Total Non Current Assets | $20,521,000 | $18,016,000 | $91,970,000 | $117,261,000 |
| Other Non Current Assets | $361,000 | $18,016,000 | $22,246,000 | $7,354,000 |
| Current Assets | $99,073,000 | $196,509,000 | $331,559,000 | $492,826,000 |
| Other Current Assets | $1,121,000 | $1,139,000 | $6,683,000 | $4,353,000 |
| Assets Held For Sale Current | $0 | $110,849,000 | $65,776,000 | - |
| Prepaid Assets | $1,015,000 | $1,903,000 | $4,855,000 | $9,730,000 |
| Inventory | $3,743,000 | $3,155,000 | $17,173,000 | $40,436,000 |
| Receivables | $4,216,000 | $28,981,000 | $33,621,000 | $16,299,000 |
| Other Receivables | $4,000,000 | $28,500,000 | $28,500,000 | - |
| Accounts Receivable | $216,000 | $481,000 | $5,121,000 | $16,299,000 |
| Cash Cash Equivalents And Short Term Investments | $88,978,000 | $50,482,000 | $203,451,000 | $422,008,000 |
| Cash And Cash Equivalents | $47,872,000 | $50,482,000 | $81,553,000 | $155,700,000 |
| Cash Equivalents | $45,563,000 | $48,478,000 | $50,292,000 | $19,881,000 |
| Cash Financial | $2,309,000 | $2,004,000 | $31,261,000 | $135,819,000 |
| Debt | ||||
| Net Debt | - | $22,610,000 | - | - |
| Total Debt | - | $73,092,000 | $149,614,000 | $89,885,000 |
| Long Term Debt And Capital Lease Obligation | - | $73,092,000 | $136,967,000 | $79,593,000 |
| Long Term Debt | - | $73,092,000 | $71,934,000 | - |
| Current Debt And Capital Lease Obligation | - | - | $12,647,000 | $10,292,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $115,119,000 | $398,160,000 | $585,728,000 | $611,567,000 |
| Total Non Current Liabilities Net Minority Interest | $85,877,000 | $264,854,000 | $368,060,000 | $338,005,000 |
| Other Non Current Liabilities | $85,622,000 | $76,698,000 | $72,034,000 | $72,690,000 |
| Liabilities Heldfor Sale Non Current | $0 | $356,000 | $1,504,000 | $49,333,000 |
| Non Current Deferred Liabilities | $255,000 | $114,708,000 | $157,555,000 | $185,722,000 |
| Current Liabilities | $29,242,000 | $133,306,000 | $217,668,000 | $273,562,000 |
| Other Current Liabilities | $3,155,000 | $70,293,000 | $81,434,000 | $7,248,000 |
| Current Deferred Liabilities | $5,314,000 | $27,290,000 | $12,740,000 | $12,739,000 |
| Payables And Accrued Expenses | $20,773,000 | $35,723,000 | $110,847,000 | $243,283,000 |
| Payables | $3,745,000 | $5,064,000 | $15,778,000 | $38,449,000 |
| Accounts Payable | $3,745,000 | $5,064,000 | $15,778,000 | $30,758,000 |
| Total Tax Payable | - | - | $6,615,000 | $7,691,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-30,038,000 | $-225,602,000 | $-204,166,000 | $-21,447,000 |
| Total Equity Gross Minority Interest | $4,475,000 | $-183,635,000 | $-162,199,000 | $-1,480,000 |
| Stockholders Equity | $-30,038,000 | $-225,602,000 | $-204,166,000 | $-21,447,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,182,000 | $-5,732,000 | $-6,875,000 | $-5,720,000 |
| Other Equity Adjustments | $-2,182,000 | $-5,732,000 | $-6,875,000 | $-5,720,000 |
| Retained Earnings | $-1,706,047,000 | $-1,889,499,000 | $-1,841,920,000 | $-1,557,688,000 |
| Long Term Equity Investment | - | - | $5,290,000 | $5,061,000 |
| Other | ||||
| Ordinary Shares Number | $4,046,827 | $4,036,680 | $3,950,809 | $3,766,640 |
| Share Issued | $4,046,827 | $4,036,680 | $3,950,809 | $3,766,640 |
| Tangible Book Value | $-30,038,000 | $-225,602,000 | $-204,166,000 | $-21,447,000 |
| Invested Capital | $-30,038,000 | $-152,510,000 | $-132,232,000 | $-21,447,000 |
| Working Capital | $69,831,000 | $63,203,000 | $113,891,000 | $219,264,000 |
| Total Capitalization | $-30,038,000 | $-152,510,000 | $-132,232,000 | $-21,447,000 |
| Minority Interest | $34,513,000 | $41,967,000 | $41,967,000 | $19,967,000 |
| Additional Paid In Capital | $1,677,179,000 | $1,668,620,000 | $1,643,641,000 | $1,541,019,000 |
| Capital Stock | $1,012,000 | $1,009,000 | $988,000 | $942,000 |
| Common Stock | $1,012,000 | $1,009,000 | $988,000 | $942,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $255,000 | $114,708,000 | $157,555,000 | $185,722,000 |
| Current Deferred Revenue | $5,314,000 | $27,290,000 | $12,740,000 | $12,739,000 |
| Current Accrued Expenses | $17,028,000 | $30,659,000 | $95,069,000 | $204,834,000 |
| Investments And Advances | $20,160,000 | $0 | $5,290,000 | $9,409,000 |
| Other Investments | $20,160,000 | $0 | $0 | $4,348,000 |
| Work In Process | $3,743,000 | $3,155,000 | $16,386,000 | $36,003,000 |
| Other Short Term Investments | $41,106,000 | $0 | $121,898,000 | $266,308,000 |
| Capital Lease Obligations | - | $0 | $77,680,000 | $89,885,000 |
| Long Term Capital Lease Obligation | - | $0 | $65,033,000 | $79,593,000 |
| Current Capital Lease Obligation | - | $0 | $12,647,000 | $10,292,000 |
| Net PPE | - | $0 | $69,724,000 | $100,498,000 |
| Accumulated Depreciation | - | $0 | $-141,378,000 | $-150,779,000 |
| Gross PPE | - | $0 | $211,102,000 | $251,277,000 |
| Leases | - | $0 | $84,920,000 | $102,580,000 |
| Machinery Furniture Equipment | - | $0 | $12,233,000 | $25,328,000 |
| Properties | - | $0 | $0 | $0 |
| Raw Materials | - | $0 | $787,000 | $1,241,000 |
| Construction In Progress | - | - | $62,000 | $204,000 |
| Other Properties | - | - | $113,949,000 | $123,165,000 |
| Finished Goods | - | - | $5,575,000 | $3,192,000 |
| Non Current Accrued Expenses | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,812,000 | $-138,265,000 | $-317,540,000 | $-184,674,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,774,000 | $-137,999,000 | $-315,021,000 | $-145,933,000 |
| Cash Flow From Continuing Operating Activities | $-4,774,000 | $-137,999,000 | $-315,021,000 | $-145,933,000 |
| Operating Gains Losses | $-48,455,000 | $-1,418,000 | $-2,363,000 | $-1,569,000 |
| Investing Activities | ||||
| Capital Expenditure | $-38,000 | $-266,000 | $-2,519,000 | $-38,741,000 |
| Investing Cash Flow | $35,419,000 | $125,993,000 | $153,657,000 | $89,116,000 |
| Cash Flow From Continuing Investing Activities | $35,419,000 | $125,993,000 | $153,657,000 | $89,116,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-86,028,000 | $-255,000 | $122,749,000 | $46,776,000 |
| Cash Flow From Continuing Financing Activities | $-86,028,000 | $-255,000 | $122,749,000 | $46,776,000 |
| Net Other Financing Charges | $-11,018,000 | $-354,000 | $-2,983,000 | $43,130,000 |
| Dividend Received Cfo | $3,947,000 | $2,230,000 | $2,255,000 | $0 |
| Issuance Of Capital Stock | - | $0 | $48,407,000 | $0 |
| Net Common Stock Issuance | - | $0 | $48,407,000 | $0 |
| Common Stock Issuance | - | $0 | $48,407,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-75,010,000 | $-40,000 | $-484,000 | $-538,000 |
| Interest Paid Supplemental Data | $7,830,000 | $16,207,000 | $6,383,000 | $104,000 |
| End Cash Position | $47,872,000 | $102,178,000 | $113,688,000 | $155,700,000 |
| Beginning Cash Position | $102,178,000 | $113,688,000 | $155,700,000 | $171,223,000 |
| Effect Of Exchange Rate Changes | $1,077,000 | $751,000 | $-3,397,000 | $-5,482,000 |
| Changes In Cash | $-55,383,000 | $-12,261,000 | $-38,615,000 | $-10,041,000 |
| Proceeds From Stock Option Exercised | $0 | $139,000 | $3,731,000 | $4,184,000 |
| Net Issuance Payments Of Debt | $-75,010,000 | $-40,000 | $73,594,000 | $-538,000 |
| Net Long Term Debt Issuance | $-75,010,000 | $-40,000 | $73,594,000 | $-538,000 |
| Long Term Debt Payments | $-75,010,000 | $-40,000 | $-484,000 | $-538,000 |
| Net Investment Purchase And Sale | $-61,158,000 | $125,213,000 | $155,520,000 | $127,851,000 |
| Sale Of Investment | $0 | $133,841,000 | $407,350,000 | $291,874,000 |
| Purchase Of Investment | $-61,158,000 | $-8,628,000 | $-251,830,000 | $-164,023,000 |
| Net Business Purchase And Sale | $96,615,000 | $0 | $656,000 | $0 |
| Sale Of Business | $96,615,000 | $0 | $656,000 | $0 |
| Net PPE Purchase And Sale | $-38,000 | $780,000 | $-2,519,000 | $-3,735,000 |
| Sale Of PPE | $0 | $1,046,000 | $0 | $6,000 |
| Purchase Of PPE | $-38,000 | $-266,000 | $-2,519,000 | $-3,741,000 |
| Change In Working Capital | $-153,032,000 | $-117,459,000 | $-119,687,000 | $70,430,000 |
| Change In Other Working Capital | $-136,429,000 | $-28,297,000 | $-28,166,000 | $-4,130,000 |
| Change In Other Current Liabilities | $-275,000 | $-79,468,000 | $-11,751,000 | $-27,791,000 |
| Change In Other Current Assets | $-94,000 | $67,316,000 | $11,960,000 | $11,171,000 |
| Change In Payables And Accrued Expense | $-73,155,000 | $-77,007,000 | $-65,303,000 | $96,498,000 |
| Change In Accrued Expense | $-45,501,000 | $-91,519,000 | $-49,789,000 | $90,589,000 |
| Change In Interest Payable | $7,996,000 | $2,271,000 | $-11,000 | $33,000 |
| Change In Payable | $-27,654,000 | $14,512,000 | $-15,514,000 | $5,909,000 |
| Change In Account Payable | $-27,654,000 | $14,512,000 | $-15,514,000 | $5,909,000 |
| Change In Prepaid Assets | $54,102,000 | $-15,550,000 | $-28,165,000 | $4,916,000 |
| Change In Inventory | $5,362,000 | $22,284,000 | $-1,695,000 | $-10,999,000 |
| Change In Receivables | $-2,543,000 | $-6,737,000 | $3,433,000 | $765,000 |
| Changes In Account Receivables | $-2,543,000 | $-6,737,000 | $3,433,000 | $765,000 |
| Stock Based Compensation | $6,576,000 | $25,215,000 | $50,767,000 | $65,601,000 |
| Asset Impairment Charge | $2,062,000 | $0 | $1,000,000 | $0 |
| Amortization Of Securities | $-72,000 | $-1,680,000 | $-5,061,000 | $1,619,000 |
| Depreciation Amortization Depletion | $748,000 | $2,692,000 | $9,930,000 | $10,604,000 |
| Depreciation And Amortization | $748,000 | $2,692,000 | $9,930,000 | $10,604,000 |
| Depreciation | $748,000 | $2,692,000 | $9,930,000 | $10,604,000 |
| Earnings Losses From Equity Investments | $-2,485,000 | $-3,969,000 | $-2,638,000 | $-1,573,000 |
| Gain Loss On Sale Of PPE | $0 | $2,551,000 | $4,000 | $-1,000 |
| Gain Loss On Sale Of Business | $-52,553,000 | $0 | - | - |
| Net Income From Continuing Operations | $183,452,000 | $-47,579,000 | $-284,232,000 | $-293,654,000 |
| Issuance Of Debt | - | $0 | $74,078,000 | $0 |
| Long Term Debt Issuance | - | $0 | $74,078,000 | $0 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-35,000,000 |
| Purchase Of Intangibles | - | - | $0 | $-35,000,000 |
| Other Non Cash Items | - | - | $32,370,000 | $1,036,000 |
| Unrealized Gain Loss On Investment Securities | - | - | $0 | $0 |
| Gain Loss On Investment Securities | - | - | $271,000 | $5,000 |
| Purchase Of Business | - | - | - | $0 |
Fetched: 2026-06-23